Abstract
Glycopeptides remain the cornerstone of the treatment of severe infections caused by methicillin resistant S. aureus. Therapeutic failures may be due to failure of removing intravascular device, or the presence of secondary foci such as endocarditis. Up to now, pharmacological failures were rather uncommon provided that adequate serum levels are obtained. However, the emergence of glycopeptide intermediate S. aureus (GISA) strains may lead to an increased risk of failure. In patients infected with GISA strains, high serum levels of glycopeptides should be maintained. For these patients combination therapy should also be investigated. © 2002 Editions scientifiques et medicales Elsevier SAS glycopeptides / S. aureus / therapeutic failures
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
